Nav: Home

New Alzheimer's disease findings to be shared at international conference

December 05, 2016

WHAT: The conference will review the most important and promising developments in Alzheimer's disease research. It encourages the exchange of ideas and techniques used to tackle one of the 21st century's most intractable problems. The aim is to accelerate the development of effective Alzheimer's disease treatments.

USC scientists will be available for embargoed interviews prior to the conference when some 1,100 worldwide leaders in Alzheimer's disease research will congregate in San Diego for a three-day event at the 9th annual conference for Clinical Trials on Alzheimer's Disease (CTAD).

Paul Aisen, director of the USC Alzheimer's Therapeutic Research Institute (ATRI), founded CTAD in 2008 along with Jacques Touchon, Bruno Vellas and Mike Weiner. Attendance at the conference will nearly triple this year compared to its inaugural year.

More than 70 researchers at USC are devoted to reimagining the way Alzheimer's disease is studied, diagnosed, prevented, treated and -- perhaps one day -- cured. These are the topics six USC scientists will speak about at CTAD:
  • Phase 3 clinical trial that used Eli Lilly's drug solanezumab in people with mild dementia
  • The search for Alzheimer's disease biomarkers in people with Down syndrome: a genetically predisposed population
  • Stem cell use and regenerative therapeutics for Alzheimer's disease treatment
  • Phase 3 clinical trial that used the drug LMTM on people with mild Alzheimer's disease to inhibit the accumulation of tau proteins
  • Safety and efficacy of low-dose Ladostigil in patients with mild cognitive impairment
  • The APOE gene and low levels of amyloid beta protein 42 (Abeta42) in cerebrospinal fluid may influence the activity of omega-3 fatty acids, which enhance synaptic plasticity, learning and memory
  • Continued progress on Alzheimer's disease trial design
  • Using algorithms to automatically classify adverse effects in clinical studies of Alzheimer's disease
  • Using an interactive, open-source platform to monitor risk in Alzheimer's disease clinical trials

WHEN: Thursday, Dec. 8 -- Saturday, Dec. 10

The presentation "EXPEDITION3: A phase 3 trial of solanezumab in mild dementia due to Alzheimer's disease" will take place from 6:15-7:45 p.m. PST on Thursday, Dec. 8 and will be streamed live at

WHERE: Marriott Marquis San Diego Marina
333 West Harbor Drive
San Diego, CA 92101

  • Paul Aisen, director of the USC Alzheimer's Therapeutic Research Institute
  • Michael Rafii, clinical director of the USC Alzheimer's Therapeutic Research Institute
  • Lon Schneider, director of the USC California Alzheimer's Disease Center
  • Hussein Yassine, assistant professor of medicine at the Keck School of Medicine of USC
  • Gustavo Jimenez-Maggiora, director of informatics at the USC Alzheimer's Therapeutic Research Institute
  • Rema Raman, director of biostatistics at the USC Alzheimer's Therapeutic Research Institute

RSVP for PRESS PASS: Call (213) 300-1381 or email

University of Southern California

Related Clinical Trials Articles:

Giving children a voice in clinical trials
Children as young as 8 years old with incurable cancer can reliably characterize the impact an experimental therapy has on their symptoms and quality of life -- even at the earliest stages of drug development -- making self-reported patient outcomes a potential new clinical trial endpoint.
Better health for women involved in clinical trials
Women who participate in obstetric and gynecology clinical trials experience improved health outcomes compared to those who are not involved in trials, according to research by Queen Mary University of London.
Final artificial pancreas clinical trials now open
Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.
Why the bar needs to be raised for human clinical trials
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
New drug formulary will help expedite use of agents in clinical trials
The National Cancer Institute (NCI) today launched a new drug formulary (the 'NCI Formulary') that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational agents for use in preclinical studies and cancer clinical trials.
More Clinical Trials News and Clinical Trials Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...